Investigators

Summary

Dr. Dorritie was previously involved in laboratory research focused on the development of novel therapeutic agents for acute myeloid leukemia. More recently, she has shifted her focus to early phase clinical trials in hematologic malignancies, specifically immune therapies for lymphoma and multiple myeloma. She is a member of the Cancer Therapeutics Team.  She has played a key role in the development of the chimeric antigen receptor (CAR) T-cell and bispecific antibody programs at UPMC and serves as lead or co-investigator on several clinical clinical trials.